Cardiac Wire attended its first ever Heart Failure Society of America meeting this year, exploring everything from the latest pharmaceutical advancements to the complex relationship between cardio-renal health and beyond. Here are some of the big takeaways from HFSA 2025.
Heart Failure Comes in Many Forms: While the gold-standard for diagnosing heart failure is still tied to left ventricular ejection fraction, what causes decreased LVEF varies greatly from congenital defects, to cardiometabolic causes, and even gene over-expression. This was reflected in the studies presented by researchers and the solutions offered by companies.
Pharma Has a Strong HF Priority: Among the booths and studies at HFSA, both the research and floor space were dominated by pharma companies, underscoring how many of the treatments for HF focus on either biochemically reducing symptoms, improving quality of life, or addressing the root cause of HF.
Patient Monitoring is Central to HF Treatment: Whether it’s getting the dose right, or making sure a patient’s heart function is steady, one thing was clear from this year’s studies: data drives the decisions clinicians make on the individual level. Stats like serum potassium or arterial pressure vary from patient to patient, so no two HF treatments are really the same.
Transplants are Still Inevitable: Even with all the discussion around how to best treat heart failure, there still isn’t a cure in sight, meaning that the final option for many patients with failing hearts is a transplant.
Many HF Forms Are Still Preventable: Though it may seem like a discouraging takeaway, the lack of a definitive cure for HF highlights just how important prevention is, with the HFSA now moving in the direction of prioritizing prevention rather than just treating it when it happens.
